Skip to main content

Advertisement

SpringerLink
Log in

Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the effects of full-dose, half-dose, and half-dose-half-fluence photodynamic therapy (PDT) in central serous chorioretinopathy (CSC).

Methods

This retrospective study enrolled patients with CSC who received full-dose (verteporfin 6 mg/m2), half-dose (verteporfin 3 mg/m2), and half-dose-half-fluence (verteporfin 3 mg/m2 and light energy reduced to 25 J/cm2) PDT. We measured visual acuity, subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) thickness, and choroidal vascularity index (CVI) before and 3 months after PDT.

Results

Forty-three eyes (42 patients) were analyzed. Full-dose and half-dose groups showed improved vision (P = 0.023, 0.004, respectively), but half-dose-half-power group was not significantly improved (P = 0.254). SFCT in all three groups were significantly decreased (P = 0.005, 0.004, 0.002, respectively). SRF thicknesses in full-dose and half-dose groups showed significant decreases (P = 0.005, < 0.001, respectively). Half-dose-half-fluence group demonstrated the decrease but it was not statistically significant (P = 0.084). CVI were decreased in full-dose and half-dose groups (all P = 0.005). However, in the half-dose-half-fluence group, CVI was increased (P = 0.003).

Conclusion

Full-dose and half-dose PDT were both effective in CSC treatment. Half-dose PDT can be considered to reduce complications. The effect of half-dose-half-fluence PDT was less clear than the other two protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87(12):1453–1458

    Article  PubMed  PubMed Central  Google Scholar 

  2. Taban M, Boyer DS, Thomas EL, Taban M (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137(6):1073–1080. https://doi.org/10.1016/j.ajo.2004.01.043

    Article  PubMed  Google Scholar 

  3. Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF, Macula Society Csc Collaborative Study Group R, Education C, Website C (2014) Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121(5):1073–1078. https://doi.org/10.1016/j.ophtha.2013.11.040

    Article  PubMed  Google Scholar 

  4. Group ToA-rMDWPTTS (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol 117(10):1329–1345

    Article  Google Scholar 

  5. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119(2):198–207

    Google Scholar 

  6. Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58(2):103–126. https://doi.org/10.1016/j.survophthal.2012.07.004

    Article  PubMed  PubMed Central  Google Scholar 

  7. Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28(8):944–957. https://doi.org/10.1038/eye.2014.134

    Article  CAS  Google Scholar 

  8. Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelen ME (2016) A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 170:91–99. https://doi.org/10.1016/j.ajo.2016.07.026

    Article  PubMed  Google Scholar 

  9. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90(7):869–874. https://doi.org/10.1136/bjo.2006.090282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S (2013) Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 33(2):316–323. https://doi.org/10.1097/IAE.0b013e318280769c

    Article  CAS  PubMed  Google Scholar 

  11. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112(8):1057–1062

    Article  CAS  PubMed  Google Scholar 

  12. Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121(1):26–34

    Article  CAS  PubMed  Google Scholar 

  13. Hua R, Liu L, Li C, Chen L (2014) Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagn Photodyn Ther 11(4):519–525. https://doi.org/10.1016/j.pdpdt.2014.07.005

    Article  CAS  Google Scholar 

  14. Agrawal R, Chhablani J, Tan KA, Shah S, Sarvaiya C, Banker A (2016) Choroidal vascularity index in central serous chorioretinopathy. Retina 36(9):1646–1651. https://doi.org/10.1097/IAE.0000000000001040

    Article  PubMed  Google Scholar 

  15. Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, Iida T (2017) Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol 101(4):433–437. https://doi.org/10.1136/bjophthalmol-2016-308921

    Article  PubMed  Google Scholar 

  16. Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M (2011) Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Retina 31(9):1912–1920. https://doi.org/10.1097/IAE.0b013e3182252aa8

    Article  CAS  PubMed  Google Scholar 

  17. Maruko I (2012) Evaluation of the choroid in central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 116(11):1062–1079

    PubMed  Google Scholar 

  18. Tan R, Agrawal R, Taduru S, Gupta A, Vupparaboina K, Chhablani J (2018) Choroidal vascularity index in retinitis pigmentosa: an OCT study. Ophthalmic Surg Lasers Imaging Retina 49(3):191–197. https://doi.org/10.3928/23258160-20180221-07

    Article  PubMed  Google Scholar 

  19. Kinoshita T, Mitamura Y, Mori T, Akaiwa K, Semba K, Egawa M, Mori J, Sonoda S, Sakamoto T (2016) Changes in choroidal structures in eyes with chronic central serous chorioretinopathy after half-dose photodynamic therapy. PLoS One 11(9):e0163104. https://doi.org/10.1371/journal.pone.0163104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23(6):752–763

    Article  PubMed  Google Scholar 

  21. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23(3):288–298

    Article  PubMed  Google Scholar 

  22. Nicolo M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153(3):474–480 e471. https://doi.org/10.1016/j.ajo.2011.08.015

    Article  PubMed  Google Scholar 

  23. Nicolo M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F (2014) Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 157(5):1033–1037. https://doi.org/10.1016/j.ajo.2014.01.022

    Article  PubMed  Google Scholar 

  24. Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122(3):555–561. https://doi.org/10.1016/j.ophtha.2014.09.034

    Article  PubMed  Google Scholar 

  25. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115(10):1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2016R1A6A1A03010528).

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Wookyung Park, Mirinae Kim, Rae Young Kim & Young-Hoon Park

  2. Catholic Institute for Visual Science, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea

    Wookyung Park, Mirinae Kim, Rae Young Kim & Young-Hoon Park

Authors
  1. Wookyung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mirinae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rae Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Young-Hoon Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young-Hoon Park.

Ethics declarations

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This study has been presented as a poster at ARVO 2019 annual meeting.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Park, W., Kim, M., Kim, R.Y. et al. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol 257, 2155–2161 (2019). https://doi.org/10.1007/s00417-019-04426-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04426-8

Keywords

Search

Navigation